Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

NCT06913023 · Not yet recruiting

Last updated 2026-09-22

This clinical trial is testing whether semaglutide can help prevent diabetes in people who have received a kidney transplant.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 37 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-09 · est. completion 2029-12

Where 2 sites · Canada

What this study is testing ClinicalTrials.gov NCT06913023 ↗

Description as written by the study sponsor.

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).

Treatments tested

Semaglutide 0.25 mg Drug

Subcutaneous semaglutide 0.25mg for 4 weeks.
Semaglutide 0.5 mg Drug

Subcutaneous semaglutide 0.5mg for 4 weeks.
Semaglutide 1.0 mg Drug

Subcutaneous semaglutide 1.0 mg for 4 weeks.
Semaglutide 1.7mg subcutaneous Drug

Subcutaneous semaglutide 1.7 mg for 4 weeks
Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] Drug

Subcutaneous semaglutide 2.4 mg for 8 weeks

Main thing measured	2-hour OGTT
Sponsor	University Health Network, Toronto
Conditions studied	Kidney Transplant Recipient
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06913023 ↗